EL7.AI
Mergers & AcquisitionsMedium•25 October 2026•
4 min read

Bolt’s $120 Million Financing Accompanies Prana Acquisition and Ownership Reshuffle

Key Facts

1Bolt completed its acquisition of Prana on October 23, 2026, through an all-stock reverse merger.
2The private placement was agreed at $120 million in upfront proceeds, with the potential to raise an additional $60 million if warrants are exercised.
3After the transaction and financing, former Bolt shareholders, former Prana shareholders and private placement investors were estimated to hold 6.9%, 51.7% and 41.4%, respectively.
4The company expects its operating cash runway to extend into 2028.

Bolt Biotherapeutics completed its acquisition of Prana Therapies on October 23, 2026, through an all-stock reverse merger, according to the company’s filing with the U.S. Securities and Exchange Commission. The deal was accompanied by a private placement with $120 million in upfront gross proceeds, with the potential to raise about $60 million more if the warrants are exercised for cash. The financing was expected to close on October 26, so its timing differs from the acquisition completion date. Bolt says the expected proceeds will provide an operating cash runway into 2028. The deal puts the PRA-216 program at the forefront of the development pipeline the company will pursue after combining the two entities.

EL7 data show BOLT shares closed at $6.27 on October 23, compared with a close of $4.19 in the previous session, on October 22. The higher close came on the day the deal was completed, while financing details and ownership allocation were part of the disclosures related to the transaction. The closing price record alone does not establish the stock’s intraday trading path. Closing prices provide a time reference for the stock’s movement around the announcement, while the financing was still scheduled to close after the trading day cited. The company links the financing to extending its capacity to operate its clinical programs.

After the transaction and financing, former Bolt shareholders were estimated to own about 6.9% of the common stock on a fully diluted basis, compared with 51.7% for former Prana shareholders and 41.4% for private placement investors, according to the SEC filing. The allocation reflects the transfer of the largest ownership stake to former Prana shareholders, with a substantial stake also held by investors participating in the financing. These percentages are calculated after the financing and on a fully diluted basis. The structure would make former Prana shareholders and new investors the principal stakeholders in the combined company. The announced percentages remain estimates tied to completion of the deal and financing.

The financing marks a significant change in the liquidity position Bolt described before the deal. In its annual report, the company said it had $31.8 million in cash, cash equivalents and marketable securities at the end of 2025, and that those resources would not be sufficient to fund operations for the following twelve months under its plan at the time. The report also cited substantial doubt about the company’s ability to continue as a going concern. According to the same report, Bolt had generated no product revenue since its founding. It posted a net loss of $33.4 million in 2025, down from $63.1 million in 2024, underscoring the reliance of its plans on financing to continue development.

The development pipeline is centered on PRA-216, a bispecific antibody targeting IL-4Rα and TSLP. The therapy is being developed in Phase 2 trials for asthma, chronic obstructive pulmonary disease and atopic dermatitis, while the company plans a Phase 2 study for eosinophilic esophagitis. Sheila Gujrathi, Prana’s former founding partner and former chief executive, said the deal and financing “provide the resources to advance PRA-216 through multiple Phase 2 readouts in 2027, while continuing to expand the INSPIRE platform pipeline.” The platform generates multispecific antibodies, according to the company’s statement. The announced development plan therefore combines a defined clinical program with expansion of the research platform.

Bolt expects patient data from all four PRA-216 trials beginning in the second quarter and through the fourth quarter of 2027, according to the statement accompanying its filing. This period spans several clinical readouts and is the next milestone the company identified after the financing. It also announced that it would hold a conference call and webcast on October 26, 2026, at 8:30 a.m. Eastern Time to discuss the deal, financing and development pipeline. The call is scheduled for the same day as the expected close of the private placement. The company is expected to provide additional details about the transaction and its clinical programs during the call.